Ainos Inc. announces VELDONA® clinical trial for oral warts in HIV+ patients, set to begin at National Taiwan University Hospital.

On September 20, 2024, Ainos, Inc. announced that Water Tower Research has released a note on its VELDONA® clinical trial, targeting oral warts in HIV+ patients. Set to begin by November 2024 at National Taiwan University Hospital, the trial will involve 40 subjects and aims for a 75% reduction in wart surface area over 24 weeks. VELDONA® has received Orphan Drug Designation from the FDA, addressing a significant need for treatment options in this patient group.

September 20, 2024
7 Articles